Literature DB >> 1309782

Purification and characterization of the carboxyl-terminal transactivation domain of Vmw65 from herpes simplex virus type 1.

L Donaldson1, J P Capone.   

Abstract

A glutathione S-transferase fusion to the COOH-terminal acidic transactivation domain of Vmw65 from herpes simplex virus type 1 was overexpressed in Escherichia coli and isolated by affinity chromatography on glutathione-Sepharose. Following cleavage of the fusion protein with thrombin, the transactivation domain was purified to homogeneity by ion exchange chromatography yielding approximately 0.6 mg of protein/liter of bacterial culture. Equilibrium sedimentation analysis showed the purified polypeptide to be monomeric; however, it displayed aberrant electrophoretic and chromatographic properties. Contrary to secondary structure predictions, circular dichroism spectroscopy demonstrated that this transactivation domain was devoid of significant alpha-helical structure at physiological conditions. The polypeptide, however, became notably more structured under hydrophobic conditions or at low pH, suggesting that it was sensitive to its environment. Near-UV circular dichroism suggested that phenylalanyl and tyrosyl residues were under influence from tertiary structure.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309782

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Natively unfolded proteins: a point where biology waits for physics.

Authors:  Vladimir N Uversky
Journal:  Protein Sci       Date:  2002-04       Impact factor: 6.725

2.  The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.

Authors:  J M Hardwick; L Tse; N Applegren; J Nicholas; M A Veliuona
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Requirements for chromatin modulation and transcription activation by the Pho4 acidic activation domain.

Authors:  P C McAndrew; J Svaren; S R Martin; W Hörz; C R Goding
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

4.  Transient-state kinetic analysis of transcriptional activator·DNA complexes interacting with a key coactivator.

Authors:  Amberlyn M Wands; Ningkun Wang; Jenifer K Lum; John Hsieh; Carol A Fierke; Anna K Mapp
Journal:  J Biol Chem       Date:  2011-02-12       Impact factor: 5.157

5.  The embryonic transcription factor stage specific activator protein contains a potent bipartite activation domain that interacts with several RNA polymerase II basal transcription factors.

Authors:  J DeFalco; G Childs
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

6.  Extensive mutagenesis of a transcriptional activation domain identifies single hydrophobic and acidic amino acids important for activation in vivo.

Authors:  M B Sainz; S A Goff; V L Chandler
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

7.  Crystal structure of the conserved core of the herpes simplex virus transcriptional regulatory protein VP16.

Authors:  Y Liu; W Gong; C C Huang; W Herr; X Cheng
Journal:  Genes Dev       Date:  1999-07-01       Impact factor: 11.361

8.  Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor.

Authors:  K Dahlman-Wright; H Baumann; I J McEwan; T Almlöf; A P Wright; J A Gustafsson; T Härd
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Transcriptional activation by herpes simplex virus type 1 VP16 in vitro and its inhibition by oligopeptides.

Authors:  T J Wu; G Monokian; D F Mark; C R Wobbe
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

10.  The AD1 transactivation domain of E2A contains a highly conserved helix which is required for its activity in both Saccharomyces cerevisiae and mammalian cells.

Authors:  M E Massari; P A Jennings; C Murre
Journal:  Mol Cell Biol       Date:  1996-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.